Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,225,474

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,225,474 protect, and when does it expire?

Patent 6,225,474 protects ULORIC and is included in one NDA.

This patent has sixty-one patent family members in thirty-four countries.

Summary for Patent: 6,225,474
Title: Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
Abstract:The present invention provides a technique of selectively producing a desired polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid. The present invention also provides a method of producing various polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, which comprises crystallizing under the conditions defined by a specific temperature and a composition of a mixed solvent of methanol and water, and polymorphs obtained by the method. The present invention further provides a method of producing the other polymorphs or amorphous compounds by drying a specific polymorph under a reduced pressure with heating, and the other polymorphs or amorphous compounds obtained by the method.
Inventor(s): Matsumoto; Koichi (Iwakuni, JP), Watanabe; Kenzo (Iwakuni, JP), Hiramatsu; Toshiyuki (Iwakuni, JP), Kitamura; Mitsutaka (Higashi-Hiroshima, JP)
Assignee: Teijin Limited (Osaka, JP)
Application Number:09/485,861
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,225,474
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,225,474

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,225,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-173079Jun 19, 1998
PCT Information
PCT FiledJune 18, 1999PCT Application Number:PCT/JP99/03258
PCT Publication Date:December 23, 1999PCT Publication Number: WO99/65885

International Family Members for US Patent 6,225,474

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 449765   Start Trial
Austria 522512   Start Trial
Australia 4289299   Start Trial
Australia 748026   Start Trial
Bulgaria 104159   Start Trial
Bulgaria 64734   Start Trial
Brazil 9906539   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.